Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The FDA accepted the Dako Omnis panel to establish sufferers with colorectal most cancers with mismatch restore deficiency.The mismatch restore immunohistochemical panel pharmDx (Dako Omnis)...
CURE spoke with an professional concerning the wants of youngsters in households residing with most cancers throughout back-to-school season.For youngsters in households which...
